UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Annals of oncology, 2020-12, Vol.31 (12), p.1623-1649

2020

Volltextzugriff (PDF)

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

Annals of oncology, 2020-05, Vol.31 (5), p.590-598

2020

Volltextzugriff (PDF)

Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?

Annals of oncology, 2013-02, Vol.24 (2), p.283-291

2013

Volltextzugriff (PDF)

Inhibiting HSP90 to treat cancer: a strategy in evolution

Current molecular medicine, 2012-11, Vol.12 (9), p.1108-1124

2012

Volltextzugriff (PDF)

1962 The use of trastuzumab in patients with early breast cancer: A multi-institutional study

European journal of cancer (1990), 2015-09, Vol.51, p.S320-S320

2015

Volltextzugriff (PDF)

1965 Patterns of care and relative effectiveness of aromatase inhibitors compared to tamoxifen in patients with early breast cancer: A multi-institutional study

European journal of cancer (1990), 2015-09, Vol.51, p.S322-S322

2015

Volltextzugriff (PDF)

1961 Variation in the chemotherapy use patterns for patients with stage I breast cancer: A multi-institutional study

European journal of cancer (1990), 2015-09, Vol.51, p.S320-S320

2015

Volltextzugriff (PDF)

Brain Metastases After Breast-conserving Therapy for Early-stage Breast Cancer: Incidence and Characteristics by Subtype

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S188-S188

2012

Volltextzugriff (PDF)

Lower-Dose Stereotactic Radiosurgery for Small Brain Metastases: Local Control and Toxicity

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S320-S321

2014

Volltextzugriff (PDF)

Reevaluating the role of antibody–drug conjugates in the treatment of patients with brain metastases

Annals of oncology, 2020-10, Vol.31 (10), p.1279-1281

Lin, N.U.

2020

Volltextzugriff (PDF)

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

Annals of oncology, 2015-01, Vol.26 (1), p.113-119

2015

Volltextzugriff (PDF)

Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?

Annals of oncology, 2024-01, Vol.35 (1), p.10-14

2024

Volltextzugriff (PDF)

Expanding the role of systemic therapy for patients with active, HER2-positive breast cancer brain metastases

ESMO open, 2022-12, Vol.7 (6), p.100596-100596, Article 100596

Lin, N.U.

2022

Volltextzugriff (PDF)

Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

Annals of oncology, 2013-06, Vol.24 (6), p.1526-1533

2013

Volltextzugriff (PDF)

335TiP Open-label, multinational, multicenter, phase IIIb/IV study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer (HER2+ BC): DESTINY-Breast12

Annals of oncology, 2021-09, Vol.32, p.S512-S513

2021

Volltextzugriff (PDF)

How we treat HER2-positive brain metastases

ESMO open, 2021-10, Vol.6 (5), p.100256-100256, Article 100256

2021

Volltextzugriff (PDF)

Antibody-drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here?

ESMO open, 2024-05, Vol.9 (5), p.102990-102990, Article 102990

2024

Volltextzugriff (PDF)

285P Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study

Annals of oncology, 2023-10, Vol.34, p.S298-S298

2023

Volltextzugriff (PDF)

475P Dynamics of TROP2 expression in triple-negative breast cancer

Annals of oncology, 2023-10, Vol.34, p.S380-S381

2023

Volltextzugriff (PDF)

484P Multi-platform characterization of HER2 expression in triple-negative breast cancer

Annals of oncology, 2023-10, Vol.34, p.S385-S385

2023

Volltextzugriff (PDF)

382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer

Annals of oncology, 2023-10, Vol.34, p.S338-S338

2023

Volltextzugriff (PDF)

Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases

Annals of oncology, 2020-09, Vol.31 (9), p.1231-1239

2020

Volltextzugriff (PDF)

Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?

Annals of oncology, 2022-03, Vol.33 (3), p.234-238

2022

Volltextzugriff (PDF)

1MO Prognostic and biologic significance of HER2-low expression in early breast cancer

Annals of oncology, 2022-05, Vol.33, p.S124-S124

2022

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Oncology
(17)
Humans
(16)
Breast Neoplasms - Drug Therapy
(12)
Female
(11)
Breast Cancer
(9)
Hematology, Oncology And Palliative Medicine
(5)
Lapatinib
(5)
Receptor, Erbb-2 - Metabolism
(5)
Treatment Outcome
(5)
Tumors
(5)
Antineoplastic Agents
(4)
Biological And Medical Sciences
(4)
Breast Neoplasms - Genetics
(4)
Gynecology. Andrology. Obstetrics
(4)
Mammary Gland Diseases
(4)
Medical Sciences
(4)
Trastuzumab
(4)
Ado-Trastuzumab Emtansine
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(21)
Esmo Open
(7)
European Journal Of Cancer
(3)
International Journal Of Radiation Oncology, Biology, Physics
(3)
Neuro-Oncology
(2)
Oncogene
(2)
Breast Cancer Research And Treatment
(1)
Breast Diseases
(1)
Current Molecular Medicine
(1)

4 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?

Inhibiting HSP90 to treat cancer: a strategy in evolution

1962 The use of trastuzumab in patients with early breast cancer: A multi-institutional study

1965 Patterns of care and relative effectiveness of aromatase inhibitors compared to tamoxifen in patients with early breast cancer: A multi-institutional study

1961 Variation in the chemotherapy use patterns for patients with stage I breast cancer: A multi-institutional study

Brain Metastases After Breast-conserving Therapy for Early-stage Breast Cancer: Incidence and Characteristics by Subtype

Lower-Dose Stereotactic Radiosurgery for Small Brain Metastases: Local Control and Toxicity

Reevaluating the role of antibody–drug conjugates in the treatment of patients with brain metastases

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?

Expanding the role of systemic therapy for patients with active, HER2-positive breast cancer brain metastases

Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

335TiP Open-label, multinational, multicenter, phase IIIb/IV study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer (HER2+ BC): DESTINY-Breast12

How we treat HER2-positive brain metastases

Antibody-drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here?

285P Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study

475P Dynamics of TROP2 expression in triple-negative breast cancer

484P Multi-platform characterization of HER2 expression in triple-negative breast cancer

382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer

Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases

Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?

1MO Prognostic and biologic significance of HER2-low expression in early breast cancer

Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022

Suchergebnisse filtern